Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2025 08:19 ET | Source: Biomerica, Inc.

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use

10-minute home test detects early kidney damage in diabetic and hypertensive patientsHypertension affects roughly one-third of adults in the UAEDiabetes impacts approximately one in four UAE nationals...
June 16, 2025 06:00 ET | Source: Averoa

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)

XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL for UK approval via MHRA’s International...
April 22, 2025 06:55 ET | Source: Arch Biopartners

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research...
April 17, 2025 08:19 ET | Source: Biomerica, Inc.

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Disease Test for Early Detection of Kidney Damage

Regulatory milestone enables commercial expansion into high-need international market10-minute test detects early signs of kidney damage using a simple urine sample Addresses global public health...
April 08, 2025 07:00 ET | Source: Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease

VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
April 02, 2025 05:00 ET | Source: Averoa

AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemiaFinal European Commission decision...
February 19, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC highlights...
February 18, 2025 07:05 ET | Source: Arch Biopartners

Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)

TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the clinical team leading the upcoming...
January 08, 2025 07:25 ET | Source: Arch Biopartners

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research Ethics...
December 09, 2024 07:00 ET | Source: FACT.MR

Renal Anemia Treatment Market Expanding at 7.5% CAGR, Poised for US$ 14.15 Billion by 2034 | Fact.MR Report

Rockville, MD, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Treatment for renal anemia, a chronic condition also known as anemia of chronic kidney disease, primarily focuses on enhancing red blood cell...